MediWoundMDWD +2.19%56 Days Payable is 436.25 as of Mar. 2026, which is 290% above its 10-year median of 111.90. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $12.44 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 700 Biotechnology companies, MediWound ranks better than 62.43% on this metric.
MediWound's average Accounts Payable for the
three
months ended in Mar. 2026 was $5.51 Mil. MediWound's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $1.15 Mil.
Hence, MediWound's Days Payable for the
three
months ended in Mar. 2026 was 436.25.
The historical rank and industry rank for MediWound's Days Payable or its related term are showing as below:
MDWD'
s Days Payable Range Over the Past 10 Years
Min: 86.32 Med: 111.9 Max: 759.95
Current: 190.63
During the past 13 years, MediWound's highest Days Payable was 759.95. The lowest was 86.32. And the median was 111.90.
MDWD's Days Payable is ranked better than 62.43% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs MDWD: 190.63
MediWound's Days Payable
increased
from Mar. 2025 (128.89) to Mar. 2026 (436.25).
It may suggest that MediWounddelayed paying its suppliers.
MediWound Days Payable Related Terms
MediWound Days Payable Historical Data
* Premium members only.
The historical data trend for MediWound's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MediWound's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediWound Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediWound's Days Payable distribution charts can be found below:
* The bar in red indicates where MediWound's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
MediWound's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediWound (MDWD) has a Days Payable of 436.25 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MediWound and its competitors. This is 290% above median its historical median of 111.90. Over the past decade, MediWound's Days Payable has ranged from 86.32 to 759.95. According to the industry distribution chart, MediWound ranks #263 out of 700 companies in the Biotechnology industry, placing it in the top 37.6%.
Is MediWound's Days Payable too high?
MediWound's current Days Payable of 436.25 is 290% above median its 10-year median of 111.90. Over the past 10 years, this metric has ranged from a low of 86.32 to a high of 759.95. The Biotechnology industry median Days Payable is 113.10. MediWound's value of 436.25 is 285.7% above this industry median. Based on the distribution chart, MediWound ranks #263 out of 700 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Days Payable compare to UNCY and ARCT?
According to the Biotechnology industry distribution chart, MediWound ranks #263 out of 700 companies for Days Payable. This puts MediWound in the upper half of its industry. The industry median Days Payable is 113.10. MediWound's value of 436.25 is 285.7% above this benchmark. Historically, MediWound's own Days Payable has ranged from 86.32 to 759.95 over the past decade. While the company's 10-year median is 111.90 vs. the industry median of 113.10, MediWound has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediWound's current Days Payable of 436.25 is 285.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MediWound and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediWound's current Days Payable is 436.25, which is 290% above median its own 10-year median of 111.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.44, compared to a current price of $15.16 — trading 21.9% above its estimated fair value. The current Days Payable is 436.25, which is 290% above median its 10-year median of 111.90 and 285.7% above the Biotechnology industry median of 113.10. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For MediWound (MDWD), the current Days Payable is 436.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediWound (MDWD) Overvalued in 2026?
Based on GuruFocus' analysis, MediWound stock appears to be overvalued.
The current stock price of $15.16 is trading 21.9% above its estimated GF Value™ of $12.44.
GuruFocus considers MediWound to be Modestly Overvalued.
Key valuation signals for MDWD:
Days Payable: 436.25 (290% above median its 10-year median of 111.90)
GF Value™: $12.44 vs. price of $15.16 (21.9% above fair value)
Industry Position: 285.7% above the Biotechnology median (#263 of 700)
No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score
Get the complete analysis for MDWD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDWD has been successfully added to your 
